RxSight (NASDAQ:RXST – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.08), Zacks reports. The company had revenue of $24.59 million for the quarter, compared to the consensus estimate of $27.19 million. RxSight had a negative return on equity of 19.85% and a negative net margin of 43.80%.
Here are the key takeaways from RxSight’s conference call:
- Third-quarter revenue fell 19% year over year to $24.6 million, while LAL procedure volume declined 11% to 23,128 units amid competitive pressure, seasonality, and internal restructuring disruption. Gross margin also decreased to 73.6%, partly due to higher inventory reserves.
- RxSight is nearly doubling its U.S. sales force and adding experienced commercial leaders to increase physician engagement, improve practice workflow integration, and drive utilization across its existing installed base. Management said high-performing practices demonstrate that stronger sales coverage and training can produce durable volume growth.
- Management expects fourth-quarter LAL sales to be roughly in line with the second quarter, implying mid- to high-single-digit sequential growth, but cautioned that competitive product trialing and restructuring-related disruption will continue through year-end. Formal 2026 guidance remains suspended, with 2027 guidance expected alongside fourth-quarter results.
- The Alcon collaboration passed its initial 120-day milestone, securing the $60 million upfront payment and allowing the companies to continue developing a partnership that management believes could expand postoperative adjustability across most of the premium IOL market.
- A comprehensive restructuring across manufacturing, corporate functions, and international operations is expected to reduce operating expenses in 2027 and beyond while preserving investment in the next-generation LAL pipeline and Alcon partnership. The company ended the quarter with $254.7 million in cash and short-term investments.
RxSight Trading Down 9.2%
NASDAQ RXST traded down $0.46 on Thursday, reaching $4.53. The stock had a trading volume of 697,675 shares, compared to its average volume of 927,290. RxSight has a 1 year low of $4.11 and a 1 year high of $13.22. The business has a 50 day moving average price of $5.30 and a 200 day moving average price of $6.31. The company has a market capitalization of $188.40 million, a price-to-earnings ratio of -3.54 and a beta of 1.21.
Analyst Upgrades and Downgrades
RXST has been the topic of several recent analyst reports. Wells Fargo & Company dropped their target price on RxSight from $9.00 to $6.00 and set an “equal weight” rating on the stock in a report on Wednesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of RxSight in a research note on Tuesday, September 8th. Piper Sandler decreased their price target on shares of RxSight from $10.00 to $8.00 and set a “neutral” rating on the stock in a research report on Wednesday. Wall Street Zen lowered RxSight from a “hold” rating to a “sell” rating in a research report on Sunday, October 25th. Finally, Stifel Nicolaus cut their target price on RxSight from $8.00 to $7.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Two equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $7.17.
Read Our Latest Stock Report on RxSight
Insider Transactions at RxSight
In related news, insider Ronald M. Md Kurtz sold 5,100 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $6.96, for a total value of $35,496.00. Following the transaction, the insider owned 71,775 shares in the company, valued at approximately $499,554. This represents a 6.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Mark Wilterding sold 7,765 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $6.96, for a total value of $54,044.40. Following the completion of the transaction, the chief financial officer owned 25,049 shares in the company, valued at $174,341.04. This represents a 23.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 16,947 shares of company stock valued at $117,951 over the last ninety days. Company insiders own 10.05% of the company’s stock.
About RxSight
RxSight, Inc is a medical technology company focused on improving visual outcomes for patients undergoing cataract surgery. The company develops and commercializes ophthalmic products that allow surgeons to customize a patient’s vision after surgery.
Its primary product is the RxSight Light Adjustable Lens, an intraocular lens implanted during cataract surgery. After implantation, the lens can be adjusted using ultraviolet light treatments delivered by the company’s Light Delivery Device, enabling physicians to refine the lens power based on the patient’s postoperative visual needs.
Featured Stories
- Five stocks we like better than RxSight
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
- South Korea’s Chip Exports Are Soaring—So Why Is This ETF Down 20%?
- Uber’s Profit Drop: A Speed Bump or Structural Shift?
- Boeing Has the Orders, the Cash Flow, and Insider Buyers, But What’s Still Missing?
Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.
